Medical evidence and health policy: a marriage of convenience? The case of proton pump inhibitors.
BACKGROUND
In Belgium, several policies regulating reimbursement of acid suppressant drugs and evidence-based recommendations for clinical practice were issued in a short period of time, creating a unique opportunity to observe their effect on prescribing.


OBJECTIVE
To describe the evolution of prescriptions for acid suppressants and explore the interaction of policies and practice recommendations with prescribing patterns.


METHODS
Monthly claims-based data for proton pump inhibitors (PPIs) and H(2)-antihistamines by general practitioners, internists and gastroenterologists were obtained from the Belgian national health insurance database (1997-2005). The evolution of reimbursed defined daily doses and expenses after introduction of reimbursement regulations and dissemination of practice recommendations was explored.


RESULTS
Recommendations had no impact on prescribing. All changes can be related to concomitant policies. Lifting reimbursement restrictions for cheaper products did not control growth or save costs in the long term. Only restricting reimbursement of all PPIs managed to curb the growth. We observed an unintended increase of non-omeprazole PPIs by gastroenterologists.


CONCLUSIONS
Reimbursement policies influence prescribing, but their effect can be unintended. A dialogue between policymakers and guideline developers, and evidence-based policies that are linked to clinical guidelines, could be an effective way to pursue both cost-containment and quality of care.
van Driel
Mieke L
ML
Department of General Practice and Primary Health Care, Ghent University, Ghent, Belgium. mieke.vandriel@ugent.be
Vander Stichele
Robert
R
De Maeseneer
Jan
J
De Sutter
An
A
Christiaens
Thierry
T
D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use; D001530:Belgium; D004363:Drug Utilization; D019317:Evidence-Based Medicine; D006291:Health Policy; D006635:Histamine H2 Antagonists / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007345:Insurance Claim Review; D007349:Insurance, Health, Reimbursement / Q000191:economics; D009313:National Health Programs / Q000191:economics / Q000458:organization & administration*; D010818:Practice Patterns, Physicians'; D054328:Proton Pump Inhibitors
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors